National Kidney Foundation Launches Race-Agnostic eGFR Community for Medication Decisions
Event summary
- National Kidney Foundation launched the IMeD-eGFR Community on July 20, 2026 to advance race-agnostic kidney function assessment for medication decisions.
- The initiative brings together pharmacists, physicians, laboratory experts, informaticists, EHR leaders, and patients to support implementation of evidence-based eGFR equations.
- NKF's Workgroup for Implementation of Race-Agnostic eGFR-Based Medication-Related Decisions is developing practical strategies for nationwide adoption.
- The transition from the Cockcroft-Gault equation to the 2021 CKD-EPI eGFR equation requires coordination across multiple healthcare stakeholders.
The big picture
The shift from race-adjusted to race-agnostic eGFR equations represents a significant evolution in kidney disease management, aligning with broader trends toward equity in healthcare. The National Kidney Foundation's initiative underscores the growing recognition of structural inequities in clinical practice and the need for evidence-based updates to long-standing protocols.
What we're watching
- Adoption Pace
- How quickly healthcare organizations will transition to the race-agnostic eGFR equation for medication-related decisions.
- Implementation Challenges
- Whether the IMeD-eGFR Community can effectively address the coordination challenges among pharmacists, clinicians, laboratories, and EHR vendors.
- Impact on Patient Outcomes
- The extent to which the new approach will improve consistency in medication-related decisions and ultimately patient care.